Berkeley, Calif.-based Iota Biosciences Inc. has raised a $15 million series A round to get into a first-in-human pilot study for its bioelectronics implants. The field of bioelectronics aims to develop super tiny implants that effectively shift fundamental disease processes via neuromodulation, thereby potentially replacing pharmaceutical treatments with a safer, more effective, nonsystemic alternative.